REVA Medical Highlights Revolutionary Advances with MOTIV® at VIVA26 Conference

REVA Medical's Breakthrough at VIVA26: Live Case Demonstration and Clinical Insights

On October 6, 2026, REVA Medical, LLC successfully captivated participants at the Vascular InterVentional Advances (VIVA) 2026 conference held in Las Vegas. The highlight of the event was a live case demonstration showcasing the MOTIV® sirolimus-eluting bioresorbable scaffold, which is gaining attention for its effectiveness in treating complex peripheral artery conditions.

Live Demonstration of the MOTIV® Technology

The live case was led by Professor Andrej Schmidt, MD, from University Hospital Leipzig. He treated a 72-year-old female patient suffering from chronic limb-threatening ischemia (CLTI), classified as Rutherford Category 5, with a non-healing ulcer. Two MOTIV scaffolds of different sizes—a 4.0 mm × 48 mm and a 3.5 mm × 24 mm—were utilized in the procedure. Notably, the treatment resulted in successful revascularization of the patient’s artery, demonstrating an impressive angiographic outcome.

This event not only underscored the scaffold's capabilities but also enhanced the visibility of bioresorbable technologies in clinical settings. The successful procedure highlighted the potential of MOTIV® to become a standard treatment option for patients facing similar vascular challenges.

Presentation of Late-Breaking Studies

The event also featured a late-breaking presentation by Dr. Ehrin Armstrong from HCA HealthOne Swedish Medical Center. He unveiled findings from a subgroup analysis of the MOTIV pivotal trial. This analysis aimed to assess clinical outcomes related to different severities of chronic limb-threatening ischemia.

The trial included 292 participants categorized under Rutherford Grades 4 and 5. This was particularly significant since the study population was remarkably complex, with 69% of the patients classified as Rutherford 5. The comparative analysis between MOTIV and standard balloon angioplasty (PTA) revealed compelling outcomes.

At the six-month mark, 87.2% of the Rutherford 4 patients treated with MOTIV achieved favorable results compared to 76.3% receiving PTA. For the Rutherford 5 group, the success rate was 77.0% for MOTIV against 55.8% for PTA. These figures were further strengthened at the twelve-month follow-up, demonstrating enduring advantages for the MOTIV treatment.

In terms of acute technical success, the MOTIV scaffold outperformed PTA, particularly evident in the more challenging Rutherford 5 cohort.

REVA Medical's Vision and Commitment

Jeffrey Anderson, President and CEO of REVA Medical, expressed enthusiasm about the event’s outcomes, stating, "Today's live case demonstration and the late-breaking MOTIV results brought the potential of our bioresorbable scaffold technology into sharp focus at VIVA26." He emphasized the importance of these treatments in improving patient quality of life.

Chronic limb-threatening ischemia is recognized as the most severe phase of peripheral artery disease. It can lead to debilitating pain, persistent non-healing wounds, and potential amputation if not addressed effectively. The MOTIV bioresorbable scaffold offers a viable solution, designed to alleviate blockages, support vessel healing, and ultimately dissolve within the body over time, eliminating the need for permanent implants.

Final Thoughts and Future Directions

As REVA Medical continues to explore advancements in vascular treatments, their innovations could drastically change the landscape of care for patients with peripheral artery disease. With promising results from the MOTIV trial and successful live demonstrations, the medical community and patients alike are optimistic about the future of bioresorbable technologies.

In conclusion, the VIVA26 conference has not only spotlighted the advancements made by REVA Medical but has also paved the way for further exploration and integration of innovative treatments within clinical practices. As the demand for effective vascular solutions grows, MOTIV® remains at the forefront of these significant medical advancements.